Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial.
Adjuvant
FOLFIRINOX
Neoadjuvant
Resectable pancreatic cancer
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
08 Mar 2024
08 Mar 2024
Historique:
received:
31
08
2023
accepted:
21
01
2024
medline:
9
3
2024
pubmed:
9
3
2024
entrez:
8
3
2024
Statut:
aheadofprint
Résumé
Although addition of adjuvant chemotherapy is the current standard, the prognosis of pancreatic cancers still remains poor. The NEPAFOX trial evaluated perioperative treatment with FOLFIRINOX in resectable pancreatic cancer. This multicenter phase II trial randomized patients with resectable or borderline resectable pancreatic cancer without metastases into arm (A,) upfront surgery plus adjuvant gemcitabine, or arm (B,) perioperative FOLFIRINOX. The primary endpoint was overall survival (OS). Owing to poor accrual, recruitment was prematurely stopped after randomization of 40 of the planned 126 patients (A: 21, B: 19). Overall, approximately three-quarters were classified as primarily resectable (A: 16, B: 15), and the remaining patients were classified as borderline resectable (A: 5, B: 4). Of the 12 evaluable patients, 3 achieved partial response under neoadjuvant FOLFIRINOX. Of the 21 patients in arm A and 19 patients in arm B, 17 and 7 underwent curative surgery, and R0-resection was achieved in 77% and 71%, respectively. Perioperative morbidity occurred in 72% in arm A and 46% in arm B, whereas non-surgical toxicity was comparable in both arms. Median RFS/PFS was almost doubled in arm B (14.1 months) compared with arm A (8.4 months) in the population with surgical resection, whereas median OS was comparable between both arms. Although the analysis was only descriptive owing to small patient numbers, no safety issues regarding surgical complications were observed in the perioperative FOLFIRINOX arm. Thus, considering the small number of patients, perioperative treatment approach appears feasible and potentially effective in well-selected cohorts of patients. In pancreatic cancer, patient selection before initiation of neoadjuvant therapy appears to be critical.
Sections du résumé
BACKGROUND
BACKGROUND
Although addition of adjuvant chemotherapy is the current standard, the prognosis of pancreatic cancers still remains poor. The NEPAFOX trial evaluated perioperative treatment with FOLFIRINOX in resectable pancreatic cancer.
PATIENTS AND METHODS
METHODS
This multicenter phase II trial randomized patients with resectable or borderline resectable pancreatic cancer without metastases into arm (A,) upfront surgery plus adjuvant gemcitabine, or arm (B,) perioperative FOLFIRINOX. The primary endpoint was overall survival (OS).
RESULTS
RESULTS
Owing to poor accrual, recruitment was prematurely stopped after randomization of 40 of the planned 126 patients (A: 21, B: 19). Overall, approximately three-quarters were classified as primarily resectable (A: 16, B: 15), and the remaining patients were classified as borderline resectable (A: 5, B: 4). Of the 12 evaluable patients, 3 achieved partial response under neoadjuvant FOLFIRINOX. Of the 21 patients in arm A and 19 patients in arm B, 17 and 7 underwent curative surgery, and R0-resection was achieved in 77% and 71%, respectively. Perioperative morbidity occurred in 72% in arm A and 46% in arm B, whereas non-surgical toxicity was comparable in both arms. Median RFS/PFS was almost doubled in arm B (14.1 months) compared with arm A (8.4 months) in the population with surgical resection, whereas median OS was comparable between both arms.
CONCLUSIONS
CONCLUSIONS
Although the analysis was only descriptive owing to small patient numbers, no safety issues regarding surgical complications were observed in the perioperative FOLFIRINOX arm. Thus, considering the small number of patients, perioperative treatment approach appears feasible and potentially effective in well-selected cohorts of patients. In pancreatic cancer, patient selection before initiation of neoadjuvant therapy appears to be critical.
Identifiants
pubmed: 38459418
doi: 10.1245/s10434-024-15011-7
pii: 10.1245/s10434-024-15011-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
NIH National Cancer Institute. Surveillance, epidemiology, and end results (SEER) program; 2022. https://seer.cancer.gov/statfacts/html/pancreas.html . Accessed Jan 2023.
Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473–81. https://doi.org/10.1001/jama.2013.279201 .
doi: 10.1001/jama.2013.279201
pubmed: 24104372
Roth MT, Berlin JD. Current concepts in the treatment of resectable pancreatic cancer. Curr Oncol Rep. 2018;20(5):39. https://doi.org/10.1007/s11912-018-0685-y .
doi: 10.1007/s11912-018-0685-y
pubmed: 29582218
Al-Batran S-E, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016;17(12):1697–708. https://doi.org/10.1016/s1470-2045(16)30531-9 .
doi: 10.1016/s1470-2045(16)30531-9
pubmed: 27776843
Al-Batran S-E, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948–57. https://doi.org/10.1016/s0140-6736(18)32557-1 .
doi: 10.1016/s0140-6736(18)32557-1
pubmed: 30982686
Jang JY, Han Y, Lee H, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg. 2018;268(2):215–22. https://doi.org/10.1097/sla.0000000000002705 .
doi: 10.1097/sla.0000000000002705
pubmed: 29462005
Katz MHG, Shi Q, Meyers J, et al. Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial. JAMA Oncol. 2022;8(9):1263–70. https://doi.org/10.1001/jamaoncol.2022.2319 .
doi: 10.1001/jamaoncol.2022.2319
pubmed: 35834226
pmcid: 9284408
van Dam JL, et al. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomised controlled trials. Eur J Cancer. 2022;160:140–9. https://doi.org/10.1016/j.ejca.2021.10.023 .
doi: 10.1016/j.ejca.2021.10.023
pubmed: 34838371
Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38(16):1763–73. https://doi.org/10.1200/jco.19.02274 .
doi: 10.1200/jco.19.02274
pubmed: 32105518
pmcid: 8265386
Wolff RA. Adjuvant or neoadjuvant therapy in the treatment in pancreatic malignancies: where are we? Surg Clin North Am. 2018;98(1):95–111. https://doi.org/10.1016/j.suc.2017.09.009 .
doi: 10.1016/j.suc.2017.09.009
pubmed: 29191281
Heinrich S. Neoadjuvant therapy for pancreatic ductal adenocarcinoma-real effects or patient selection? Hepatobiliary Surg Nutr. 2018;7(4):289–91. https://doi.org/10.21037/hbsn.2018.03.11 .
doi: 10.21037/hbsn.2018.03.11
pubmed: 30221156
pmcid: 6131267
Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7(4):e1000267. https://doi.org/10.1371/journal.pmed.1000267 .
doi: 10.1371/journal.pmed.1000267
pubmed: 20422030
pmcid: 2857873
Lee YS, Lee J-C, Yang SY, Kim J, Hwang J-H. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: a systematic review and meta-analysis. Sci Rep. 2019;9(1):15662–15662. https://doi.org/10.1038/s41598-019-52167-9 .
doi: 10.1038/s41598-019-52167-9
pubmed: 31666626
pmcid: 6821820
Xu CP, Xue XJ, Liang N, Xu DG, Liu FJ, Yu XS, Zhang JD. Effect of chemoradiotherapy and neoadjuvant chemoradiotherapy in resectable pancreatic cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2014;140(4):549–59. https://doi.org/10.1007/s00432-013-1572-4 .
doi: 10.1007/s00432-013-1572-4
pubmed: 24370686
Birrer DL, Golcher H, Casadei R, et al. Neoadjuvant therapy for resectable pancreatic cancer: a new standard of care pooled data from 3 randomized controlled trials. Ann Surg. 2021;274(5):713–20. https://doi.org/10.1097/sla.0000000000005126 .
doi: 10.1097/sla.0000000000005126
pubmed: 34334656
Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–24. https://doi.org/10.1016/s0140-6736(16)32409-6 .
doi: 10.1016/s0140-6736(16)32409-6
pubmed: 28129987
Andriulli A, Festa V, Botteri E, et al. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol. 2012;19(5):1644–62. https://doi.org/10.1245/s10434-011-2110-8 .
doi: 10.1245/s10434-011-2110-8
pubmed: 22012027
Mayo SC, Gilson MM, Herman JM, et al. Management of patients with pancreatic adenocarcinoma: national trends in patient selection, operative management, and use of adjuvant therapy. J Am Coll Surg. 2012;214(1):33–45. https://doi.org/10.1016/j.jamcollsurg.2011.09.022 .
doi: 10.1016/j.jamcollsurg.2011.09.022
pubmed: 22055585
Merkow RP, Bilimoria KY, Tomlinson JS, et al. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg. 2014;260(2):372–7. https://doi.org/10.1097/sla.0000000000000378 .
doi: 10.1097/sla.0000000000000378
pubmed: 24374509
Seufferlein T, Uhl W, Kornmann M, et al. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)—a randomized phase II trial of the AIO pancreatic cancer group. Ann Oncol. 2023;34(1):91–100. https://doi.org/10.1016/j.annonc.2022.09.161 .
doi: 10.1016/j.annonc.2022.09.161
pubmed: 36209981
Sohal DPS, Duong M, Ahmad SA, et al. Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2021;7(3):421–7. https://doi.org/10.1001/jamaoncol.2020.7328 .
doi: 10.1001/jamaoncol.2020.7328
pubmed: 33475684
Tempero MA, Pelzer U, O’Reilly EM, et al. Adjuvant nab-paclitaxel + gemcitabine in resected pancreatic ductal adenocarcinoma: results from a randomized, open-label, phase III trial. J Clin Oncol. 2023;41(11):2007–19. https://doi.org/10.1200/JCO.22.01134 .
doi: 10.1200/JCO.22.01134
pubmed: 36521097
Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26(21):3496–502. https://doi.org/10.1200/jco.2007.15.8634 .
doi: 10.1200/jco.2007.15.8634
pubmed: 18640930
Golcher H, Brunner TB, Witzigmann H, et al. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlenther Onkol. 2015;191(1):7–16. https://doi.org/10.1007/s00066-014-0737-7 .
doi: 10.1007/s00066-014-0737-7
pubmed: 25252602
Grose D, McIntosh D, Jamieson N, et al. The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland. J Gastro Oncol. 2017;8(4):683–95. https://doi.org/10.21037/jgo.2017.04.01 .
doi: 10.21037/jgo.2017.04.01
Heinrich S, Pestalozzi BC, Schäfer M, et al. Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26(15):2526–31. https://doi.org/10.1200/jco.2007.15.5556 .
doi: 10.1200/jco.2007.15.5556
pubmed: 18487569
Motoi F, Unno M. Neoadjuvant treatment for resectable pancreatic adenocarcinoma: what is the best protocol? Ann Gastroenterol Surg. 2020;4(2):100–8. https://doi.org/10.1002/ags3.12311 .
doi: 10.1002/ags3.12311
pubmed: 32258974
pmcid: 7105839
O’Reilly EM, Perelshteyn A, Jarnagin WR, et al. A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann Surg. 2014;260(1):142–8. https://doi.org/10.1097/SLA.0000000000000251 .
doi: 10.1097/SLA.0000000000000251
Sahani DV, Kambadakone A, Macari M, Takahashi N, Chari S, Fernandez-del Castillo C. Diagnosis and management of cystic pancreatic lesions. AJR Am J Roentgenol. 2013;200(2):343–54. https://doi.org/10.2214/ajr.12.8862 .
doi: 10.2214/ajr.12.8862
pubmed: 23345356
Tajima H, Ohta T, Kitagawa H, et al. Pilot study of neoadjuvant chemotherapy with gemcitabine and oral S-1 for resectable pancreatic cancer. Exp Ther Med. 2012;3(5):787–92. https://doi.org/10.3892/etm.2012.482 .
doi: 10.3892/etm.2012.482
pubmed: 22969969
pmcid: 3438612
Talamonti MS, Small W Jr, Mulcahy MF, et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol. 2006;13(2):150–8. https://doi.org/10.1245/aso.2006.03.039 .
doi: 10.1245/aso.2006.03.039
pubmed: 16418882
Turrini O, Viret F, Moureau-Zabotto L, et al. Neoadjuvant 5 fluorouracil-cisplatin chemoradiation effect on survival in patients with resectable pancreatic head adenocarcinoma: a ten-year single institution experience. Oncology. 2009;76(6):413–9. https://doi.org/10.1159/000215928 .
doi: 10.1159/000215928
pubmed: 19407474
Motoi F, Kosuge T, Ueno H, et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn J Clin Oncol. 2019;49(2):190–4. https://doi.org/10.1093/jjco/hyy190 .
doi: 10.1093/jjco/hyy190
pubmed: 30608598
Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–406. https://doi.org/10.1056/NEJMoa1809775 .
doi: 10.1056/NEJMoa1809775
pubmed: 30575490
Al-Batran S-E, Hofheinz R-D, Reichart A, et al. Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: real-life results from the prospective QOLIXANE trial of the platform for outcome, quality of life and translational research on pancreatic cancer registry. Int J Cancer. 2021;148(6):1478–88. https://doi.org/10.1002/ijc.33336 .
doi: 10.1002/ijc.33336
pubmed: 33038277
Deutsche Krebsgesellschaft. Jahresbericht der zertifizierten Pankreaskarzinomzentren—Kennzahlenauswertung 2018. Available online: www.krebsgesellschaft.de/jahresberichte.html . Accessed Jan 2023.
Ferrone CR, Marchegiani G, Hong TS. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015;261(1):12–7. https://doi.org/10.1097/sla.0000000000000867 .
doi: 10.1097/sla.0000000000000867
pubmed: 25599322
Khorana AA, Mangu PB, Berlin J, et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017;35(20):2324–8. https://doi.org/10.1200/jco.2017.72.4948 .
doi: 10.1200/jco.2017.72.4948
pubmed: 28398845
Wagner M, Antunes C, Pietrasz D, et al. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. Eur Radiol. 2017;27(7):3104–16. https://doi.org/10.1007/s00330-016-4632-8 .
doi: 10.1007/s00330-016-4632-8
pubmed: 27896469
Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. S3-Leitlinie zum exokrinen Pankreaskarzinom. (Version 1.0); 2013.
Seufferlein T. Guidelines and expert consensus in the ZfG. Z Gastroenterol. 2014;52(2):179. https://doi.org/10.1055/s-0033-1356390 .
doi: 10.1055/s-0033-1356390
pubmed: 24526401
Haeberle L, Esposito I. Pathology of pancreatic cancer. Transl Gastroenterol Hepatol. 2019;4:50. https://doi.org/10.21037/tgh.2019.06.02 .
doi: 10.21037/tgh.2019.06.02
pubmed: 31304427
pmcid: 6624347
Hewitt MJ, McPhail MJ, Possamai L, Dhar A, Vlavianos P, Monahan KJ. EUS-guided FNA for diagnosis of solid pancreatic neoplasms: a meta-analysis. Gastrointest Endosc. 2012;75(2):319–31. https://doi.org/10.1016/j.gie.2011.08.049 .
doi: 10.1016/j.gie.2011.08.049
pubmed: 22248600
Verbeke C, Löhr M, Karlsson JS, Del Chiaro M. Pathology reporting of pancreatic cancer following neoadjuvant therapy: challenges and uncertainties. Cancer Treat Rev. 2015;41(1):17–26. https://doi.org/10.1016/j.ctrv.2014.11.002 .
doi: 10.1016/j.ctrv.2014.11.002
pubmed: 25434282